Led · Series A · May 2023

NewBiologix develops a proprietary DNA-based platform to engineer HEK-293 and CHO cell lines for the manufacturing of recombinant adeno-associated virus (rAAV) vectors used in gene and cell therapies. The company combines next-generation sequencing (NGS)-based genome characterization with a proprietary bioinformatics platform to drive data-driven cell line development and improve stability, integrity, and biosafety. Its engineered cell lines aim to deliver more stable rAAV production, higher quality and predictable expression, fewer empty capsids, and better batch-to-batch reproducibility. NewBiologix says these improvements should lower cost of goods sold (COGS) and enable advancement into therapies for larger patient populations beyond rare diseases. The company emerged from stealth with a $50 million (CHF 45 million) Series A led by Recipharm A/S and additional funding from co-founders Igor Fish and Nicolas Mermod. It has assembled a scientific advisory board including Mahendra Roa, Sir Gregory Winter, Anna Maurer, and Cori Gorman, and plans beta testing of cell line prototypes with collaborators by 2024 and commercial availability of viral production cell lines by 2026.

Participated · Equity · Mar 2020

Cinclus Pharma is a Swedish late-stage biopharmaceutical company developing small molecules to treat gastric acid–related diseases. Its lead candidate, linaprazan glurate, is a potassium-competitive acid blocker (P-CAB) aimed at patients unresponsive to proton pump inhibitors and for use in H. pylori eradication. The company highlights linaprazan glurate’s potential to improve acid suppression, increase antibiotic stability, and thereby reduce unnecessary antibiotic use and antimicrobial resistance. Proceeds from a 240 MSEK venture financing will advance the lead program through two Phase III clinical trials for GERD and H. pylori infection and support regulatory and commercialization efforts. Trill Impact will support ongoing clinical development and accelerate market access in select low- and middle-income countries; Nina Rawal of Trill Impact will join the board. Cinclus says the financing will accelerate its road to approval and commercialization and strengthen its investor base, which includes AP4 and Linc. Cinclus Pharma Holding AB is advancing X842, a clinical-stage drug candidate for gastroesophageal reflux disease (GERD). X842 is based on a substance initially developed by AstraZeneca and has demonstrated a favorable safety profile and pharmacokinetic characteristics in a Phase 1 study and studies including over 2,500 individuals. The company plans to use the financing to perform a Phase 2 clinical trial expected to start in the second half of 2020, cover operating costs and carry out activities to ready the program for a pivotal Phase 3 trial. Cinclus Pharma is led by CEO Kjell Andersson. Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech located in Basel, Switzerland.

Led · Equity · Dec 2015

LIDDS develops cancer treatments using a drug-delivery technology that releases medication locally in close proximity to tumors. Its lead product, Liproca® Depot (hydroxyflutamide), has shown positive clinical results without hormonal side effects. The platform provides sustained drug release, reducing dosing frequency, and can be applied to already approved drugs to potentially shorten development time and lower risk and cost. LIDDS has signed an exclusive agreement with Recipharm to scale up the production process and for commercial manufacturing of Liproca® Depot ahead of a planned Phase IIb study slated to start in 2016. As part of the agreement, Recipharm invested 5 million kronor in a directed new share issue and became the company's third-largest shareholder. LIDDS is listed on NASDAQ First North under the ticker LIDDS; Redeye AB is its Certified Adviser.

Led · Equity · Sep 2015

Xspray Pharma is a research company developing Dasynoc, an amorphous variant of BMS's cancer drug Sprycel (dasatinib). Dasynoc is positioned as a treatment for chronic myeloid leukemia and acute lymphoblastic leukemia. The company is conducting a rights issue of up to SEK 130 million to support a planned U.S. launch of Dasynoc. According to a press release, the rights issue is approximately 68% guaranteed through subscription commitments and letters of intent from the company’s largest shareholders and a new institutional investor. The proceeds are intended to fund the U.S. commercialization effort. The article does not provide additional operating metrics or prior financing details. XSpray Microparticles develops drug candidates using its proprietary HyNap™ formulation technology, with lead compound XS004 based on a well‑known protein kinase inhibitor. The company is advancing XS004 through clinical development; a consortium is investing SEK 18 million to fund its Phase I trial, with results expected in Q2 2016. Karolinska Development and KCIF Co‑Investment Fund KB will transfer their entire shareholdings in XSpray to the consortium under an earn‑out agreement. The consortium is led by Östersjöstiftelsen and Recipharm Venture Fund and also includes XSpray’s board, management and other investors. Karolinska Development retains an economic interest through the earn‑out, which may have significant future value. The divestment reportedly has no impact on Karolinska Development’s latest reported fair value and no further financial details will be disclosed.

Led · Equity · Aug 2014

Isofol Medical is a clinical‑stage pharmaceutical company focused on unmet needs in oncology. Its lead candidate, Modufolin®, is an endogenous folate‑based biomodulator designed to increase the efficacy and reduce the side effects of antimetabolite chemotherapies. Modufolin® is the key active metabolite of clinically used folate drugs and does not require metabolic activation, potentially benefiting patients irrespective of their capacity to activate folates. The compound is being evaluated in clinical trials targeting colorectal cancer and osteosarcoma, with the company reporting Phase I/II and Phase II studies. Isofol collaborates with Merck Millipore on R&D and has secured a commercial manufacturing collaboration with Recipharm for exclusive production of Modufolin®. Financially, Recipharm Venture Fund has invested SEK 8 million and Isofol reports having raised SEK 45 million during the past eight months.